

Cell Line Data Sheet for SMS-KCN

Disease: Neuroblastoma
Phase of Therapy: Diagnosis
Treatment: Cyclophosphamide, doxorubicin, radiation therapy
Disease Stage: 4
Gender: Male
Age at diagnosis: 11 months
Race: N/A
Age at sample collection: N/A
Source of Culture: Primary tumor – retroperitoneum, liver (anterior apron), lymph nodes (portal hepatis)
Primary Tumor Site: Adrenal gland
Date Established: September 1979

MYCN Patient: Amplified
MYCN Cell line: N/A
TH mRNA: Positive
p53 functionality: Functional
Telomere Mechanism N/A
ALK: R1275Q

IC90 (DIMSCAN*): CBDCA (µg/ml) CDDP (µg/ml) DOX (ng/ml) ETOP (ng/ml) L-PAM (µg/ml)
 *see reference 4 1.4 0.5 24.7 323 5.5
 CBDCA, carboplatin; CDDP, cisplatin; DOX, doxorubicin; ETOP, etoposide; L-PAM, melphalan

Growth Conditions: Please see Protocols section at <https://www.cccells.org/protocols.php>
 5% CO₂, 20% O₂, 37.0°C

Media Formulation: Please see Protocols section at <https://www.cccells.org/protocols.php>
 Cells are grown in a base medium of Iscove's Modified Dulbecco's Medium plus the following supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine, 1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous acid)

Doubling Time: 109 hours
Growth Properties: Round, teardrop-shaded neuroblasts, adherent and suspended cells, grow mostly in clumps

STR Profile: May be obtained at <https://strdb.cccells.org/>

Notes:

All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO. Each vial label contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen. All cell lines are validated with original patient sample by STR analysis.



Cell Line Data Sheet for SMS-KCN

References:

1. Reynolds CP, Biedler JL, Spengler BA, Reynolds DA, Ross RA, Frenkel EP, Smith RG: Characterization of human neuroblastoma cell lines established before and after therapy. *J Natl Cancer I.* 76:375-387, 1986. PubMed ID: 3546456
<https://www.sciencedirect.com/science/article/pii/S0002817787420187?via%3Dihub>
2. Reynolds CP, Brodeur GM, Tomayko MM, Donner L, Helson L, Seeger RC, Triche TJ: Biological classification of cell lines derived from human extra-cranial neural tumors. *Prog Clin Biol Res.* 271:291-306, 1988. PubMed ID: 3406003
<https://pubmed.ncbi.nlm.nih.gov/3406003/>
3. Keshelava N, Seeger RC, Groshen S, Reynolds CP: Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. *Cancer Research.* 58:5396-5405, 1998. PubMed ID: 9850071
<https://cancerres.aacrjournals.org/content/58/23/5396.long>
4. Keshelava N, Groshen S, Reynolds CP. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. *Cancer Chemoth Pharm.* 45: 1-8, 2000. PubMed ID: 10647494
<https://link.springer.com/article/10.1007%2FPL00006736>
5. Thiele, Carol J., McKeon, Catherine, Triche, Timothy J., Ross, Robert A., Reynolds, C. Patrick, and Israel, Mark A. (1987). Differential Protooncogene Expression Characterizes Histopathologically Indistinguishable Tumors of the Peripheral Nervous System. *J Clin Invest* 80: 804-811. PubMed ID: 2887586
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442306/>
6. Kang MH, Smith MA, Morton CL, Keshelava N, Houghton PJ, Reynolds CP. National Cancer Institute Pediatric Preclinical Testing Program: Model Description for In Vitro Cytotoxicity Testing. *Pediatr Blood Cancer.* 56: 239-249, 2011. PubMed ID: 20922763 (www.PPTPinvitro.org)
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005554/>



Cell Line Data Sheet for SMS-KCN

Cell Line Name: SMS-KCN

Low confluency (10x magnification)

High confluency (10x magnification)

Low confluency (20x magnification)

High confluency (20x magnification)